Evoke Pharma Stock In The News

EVOK Stock  USD 0.59  0.01  1.67%   
The tone or emotional content of news articles related to Evoke Pharma can affect its prices. Positive news sentiment can lead to an increase in demand for Evoke Pharma's stock, while negative news sentiment can lead to a decrease in demand. Our overall analysis of Evoke Pharma's news coverage and content from conventional and social sources shows investors' bearish mood towards Evoke Pharma. The specific impact of Evoke Pharma news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Evoke Pharma's overall financial health and prospects. It also depends on the type and quality of a news publisher.
  
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Evoke Pharma headlines in addition to utilizing other, more conventional financial analysis modules. Check out Evoke Pharma Backtesting and Evoke Pharma Hype Analysis.
For more information on how to buy Evoke Stock please use our How to buy in Evoke Stock guide.

Evoke Pharma Today Top News and Investor Outlook

Macroaxis News: globenewswire.com
Evoke Pharma Announces FDA Orange Book Listing of New GIMOTI Patent
https://www.globenewswire.com/news-release/2023/11/27/2786159/28255/en/Evoke-Pharma-Announces-FDA-Orange-Book-Listing-of-New-GIMOTI-Patent.html
 Neutral
Macroaxis News: globenewswire.com
United States Patent and Trademark Office (USPTO) Grants Another Formulation Patent Covering GIMOTI
https://www.globenewswire.com/news-release/2023/11/14/2780102/28255/en/United-States-Patent-and-Trademark-Office-USPTO-Grants-Another-Formulation-Patent-Covering-GIMOTI.html
 Neutral
Macroaxis News: globenewswire.com
Evoke Pharma Reports Third Quarter 2023 Financial Results
https://www.globenewswire.com/news-release/2023/11/09/2777384/28255/en/Evoke-Pharma-Reports-Third-Quarter-2023-Financial-Results.html
 Bullish
Macroaxis News: globenewswire.com
Evoke Pharma & EVERSANA Unveil Cost Savi...
https://www.globenewswire.com/news-release/2023/10/31/2770197/28255/en/Evoke-Pharma-EVERSANA-Unveil-Cost-Savings-Real-World-Data-Demonstrating-Meaningfully-Reduced-Healthcare-Costs-for-Patients-Using-GIMOTI-Over-Oral-Metoclopramide-Presented-at-the-Am.html
 Bullish
Yahoo News
7 Under-the-Radar Growth Stocks Ready to Make a Splash
https://finance.yahoo.com/news/7-under-radar-growth-stocks-103017204.html
 Bullish
Macroaxis News: globenewswire.com
Evoke Pharma’s Abstract Entitled “Superi...
https://www.globenewswire.com/news-release/2023/10/18/2762379/28255/en/Evoke-Pharma-s-Abstract-Entitled-Superiority-of-Nasal-Spray-Compared-to-Orally-Administered-Metoclopramide-in-Reducing-Healthcare-Costs-in-Treating-Diabetic-Gastroparesis-Patients-.html
 Bullish
Macroaxis News: globenewswire.com
Evoke Pharma Receives Notice of Allowance from USPTO for GIMOTI®
https://www.globenewswire.com/news-release/2023/09/14/2743264/28255/en/Evoke-Pharma-Receives-Notice-of-Allowance-from-USPTO-for-GIMOTI.html
 Neutral
Macroaxis News: globenewswire.com
Evoke Pharma Reports Second Quarter 2023 Financial Results
https://www.globenewswire.com/news-release/2023/08/10/2722689/28255/en/Evoke-Pharma-Reports-Second-Quarter-2023-Financial-Results.html
 Bullish
Macroaxis News: globenewswire.com
Evoke Pharma and EVERSANA Announce Abstract Acceptance at 2023 American Neurogastroenterology and Motility Society (ANMS) Meeting
https://www.globenewswire.com/news-release/2023/08/07/2719710/28255/en/Evoke-Pharma-and-EVERSANA-Announce-Abstract-Acceptance-at-2023-American-Neurogastroenterology-and-Motility-Society-ANMS-Meeting.html
 Bullish
Macroaxis News: globenewswire.com
Evoke Pharma and EVERSANA Announce Abstr...
https://www.globenewswire.com/news-release/2023/07/25/2710440/28255/en/Evoke-Pharma-and-EVERSANA-Announce-Abstract-Selection-for-Plenary-Oral-Presentation-at-The-American-College-of-Gastroenterology-ACG-2023-Annual-Meeting.html
 Bullish

Evoke Pharma Past News Timeline

Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Evoke and other traded companies coverage. We help investors stay connected with Evoke headlines for the 28th of March to make an informed investment decision based on correlating the impacts of news items on Evoke Stock performance. Please note that trading solely based on the Evoke Pharma hype is not for everyone as timely availability and quick action are needed to avoid losses.
Evoke Pharma's linear event process diagram shows some of the filtered current and past headlines as well as many other corporate-specific events such as SEC filings, dividends, and regulatory reporting available to the public. This module can help Evoke Pharma investors visualize upcoming and past events in order to time the market based on Evoke Pharma noise-free hype analysis.
Evoke Pharma stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Evoke earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Evoke Pharma that are available to investors today. That information is available publicly through Evoke media outlets and privately through word of mouth or via Evoke internal channels. However, regardless of the origin, that massive amount of Evoke data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Evoke Pharma news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Evoke Pharma relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Evoke Pharma's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Evoke Pharma alpha.

Evoke Largest EPS Surprises

Earnings surprises can significantly impact Evoke Pharma's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2024-03-14
2023-12-31-0.5-0.59-0.0918 
2023-05-15
2023-03-31-0.58-0.67-0.0915 
2023-11-09
2023-09-30-0.62-0.510.1117 
2022-08-10
2022-06-30-0.6-0.71-0.1118 
2021-11-10
2021-09-30-0.84-0.720.1214 
2021-08-12
2021-06-30-0.96-0.840.1212 
View All Earnings Estimates

Evoke Pharma Stock Latest Headlines

Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Evoke Pharma Stock. Current markets are strongly bullish. About 72% of major world exchanges and indexes are currently up. See today's market update for more information.
seekingalpha News
21st of March 2024
Evoke Pharma names Matthew DOnofrio as new CEO
at seekingalpha.com 
insidermonkey News
15th of March 2024
Evoke Pharma, Inc. Q4 2023 Earnings Call Transcript
at insidermonkey.com 
Macroaxis News: globenewswire.com
14th of March 2024
Evoke Pharma Reports Fourth Quarter and Full Year 2023 Financial Results
at globenewswire.com 
Macroaxis News: globenewswire.com
7th of March 2024
Evoke Pharma to Report Fourth Quarter and Full Year 2023 Results on March 14, 2024
at globenewswire.com 
Yahoo News
14th of February 2024
Evoke Pharma Announces Closing of 7.5 Million Public Offering
at finance.yahoo.com 
Investing News at Macroaxis
9th of February 2024
Evoke Pharma sets terms for 30 million public offering
at investing.com 

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Evoke Pharma in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Evoke Pharma's short interest history, or implied volatility extrapolated from Evoke Pharma options trading.
When determining whether Evoke Pharma is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Evoke Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Evoke Pharma Stock. Highlighted below are key reports to facilitate an investment decision about Evoke Pharma Stock:
Check out Evoke Pharma Backtesting and Evoke Pharma Hype Analysis.
For more information on how to buy Evoke Stock please use our How to buy in Evoke Stock guide.
You can also try the AI Investment Finder module to use AI to screen and filter profitable investment opportunities.

Complementary Tools for Evoke Stock analysis

When running Evoke Pharma's price analysis, check to measure Evoke Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Evoke Pharma is operating at the current time. Most of Evoke Pharma's value examination focuses on studying past and present price action to predict the probability of Evoke Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Evoke Pharma's price. Additionally, you may evaluate how the addition of Evoke Pharma to your portfolios can decrease your overall portfolio volatility.
Money Managers
Screen money managers from public funds and ETFs managed around the world
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
CEOs Directory
Screen CEOs from public companies around the world
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Is Evoke Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Evoke Pharma. If investors know Evoke will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Evoke Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.33)
Revenue Per Share
1.55
Quarterly Revenue Growth
1.105
Return On Assets
(0.49)
Return On Equity
(10.35)
The market value of Evoke Pharma is measured differently than its book value, which is the value of Evoke that is recorded on the company's balance sheet. Investors also form their own opinion of Evoke Pharma's value that differs from its market value or its book value, called intrinsic value, which is Evoke Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Evoke Pharma's market value can be influenced by many factors that don't directly affect Evoke Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Evoke Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Evoke Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Evoke Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.